Certain Notch Pathway Genes Predict Survival in Cutaneous Melanoma
the Cancer Therapy Advisor take:
Cutaneous melanoma disease-specific survival may be predicted by the SNPs in Notch pathway genes, according to a study published online in Cancer Epidemiology, Biomarkers & Prevention.
The Notch signaling pathway promotes growth and aggressive metastatic potential of primary melanoma cells in human cutaneous melanoma.
In the study, 6,256 SNPs were identified in 48 Notch pathway genes in 858 patients with cutaneous melanoma who were previously included in a cutaneous melanoma genome-wide association dataset.
Results revealed four putative functional SNPs of Notch genes were both independently and jointly associated with predictive roles in survival of patients with cutaneous melanoma. The variant with the most significant predictive role was NCOR2 rs2342924 T>C (aHR= 2.71; 95% CI: 1.73, 4.23; Ptrend=9.62 × 10−7). The other three predictive SNPs were NCSTN rs1124379 G>A (Ptrend=0.005), NCOR2 rs10846684 G>A (Ptrend=0.005), and MAML2 rs7953425 G>A (Ptrend=0.013).
When using the receiver operating characteristic analysis curve, the area under the curve was significantly greater after adding the unfavorable genotype score to the model containing the identified clinicopathologic factors.
The study’s findings suggest that a potential exists for developing an improved prognostic assessment and personalized management approach for patients with cutaneous melanoma using these identified genetic variants as a genotype score of biomarkers.
Cutaneous melanoma disease-specific survival may be predicted by the SNPs in Notch pathway genes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer